dc.contributor.author |
Ghattass, Khaled Imad |
dc.date |
2013 |
dc.date.accessioned |
2015-02-03T10:23:21Z |
dc.date.available |
2015-02-03T10:23:21Z |
dc.date.issued |
2013 |
dc.date.submitted |
2013 |
dc.identifier.other |
b17890706 |
dc.identifier.uri |
http://hdl.handle.net/10938/9950 |
dc.description |
Dissertation (Ph.D.)-- American University of Beirut, Department of Biology, 2013. |
dc.description |
Chair of Committee : Dr. Nadine Darwiche, Professor, Biochemistry and Molecular Genetics Department--Advisor : Dr. Hala Gali-Muhtasib, Professor, Biology Department ; Co-advisor : Dr. Marwan El-Sabban, Professor, Anatomy, Cell Biology and Physiological Sciences Department ; Members of Committee : Dr. Makhlouf Haddadin, Professor, Chemistry Department ; Dr. Rabih Talhouk, Professor, Biology ; Dr. Richard Maroun, Professor, Vice Dean of Faculty of Arts and Sciences, University of Saint Joseph, Beirut, Lebanon. |
dc.description |
Includes bibliographical references (leaves 81-92) |
dc.description.abstract |
Tumor hypoxia poses challenges against conventional cancer treatments, however, it provides a therapeutic target for hypoxia-activated drugs. Here, we studied the effect of the hypoxia-activated synthetic quinoxaline di-N-oxide DCQ against breast cancer metastasis and identified the underlying mechanisms. The human breast cancer cell lines MCF-7 (p53 wildtype) and MDA-MB-231 (p53 mutant) were treated with DCQ under normoxia or hypoxia. Drug toxicity on non-cancerous MCF-10A breast cells was also determined. In vitro cellular responses were investigated by flow cytometry, transfection, western blotting, ELISA and migration assays. The anti-metastatic effect of DCQ was validated in the MDA-MB-231 xenograft mouse model. DCQ selectively induced apoptosis in both human breast cancer cells preferentially under hypoxia without affecting the viability of non-cancerous MCF-10A cells. Cancer cell death was associated with an increase in reactive oxygen species (ROS) independently of p53 and was inhibited by antioxidants. DCQ-induced ROS was associated with DNA damage, the downregulation of hypoxia inducible factor-1 alpha (HIF-1α), and inhibition of vascular endothelial growth factor (VEGF) secretion. In MCF-7, HIF-1α inhibition was partially via p53-activation and was accompanied by a decrease in p-mTOR protein, suggesting interference with HIF-1α translation. In MDA-MB-231, DCQ reduced HIF-1α protein levels through proteasomal-dependent degradation mechanisms. HIF-1α inhibition by DCQ blocked VEGF secretion and invasion in MCF-7 and led to the inhibition of TWIST in MDA-MB-231. Consistently, DCQ exhibited robust antitumor activity in MDA-MB-231 breast cancer mouse xenografts, enhanced animal survival, and reduced metastatic dissemination to lungs and liver. This is the first study to document the favorable effects of DCQ in vitro and in vivo against breast cancer metastasis via targeting the HIF-1α. Our data provide evidence for the clinical promise of DCQ especially against breast |
dc.format.extent |
xv, 92 leaves : illustrations (some color) ; 30 cm |
dc.language.iso |
eng |
dc.relation.ispartof |
Theses, Dissertations, and Projects |
dc.subject.classification |
D:000041 AUBNO |
dc.subject.lcsh |
Quinoxaline. |
dc.subject.lcsh |
Cancer cells. |
dc.subject.lcsh |
Breast -- Cancer. |
dc.subject.lcsh |
Apoptosis. |
dc.subject.lcsh |
Matastasis. |
dc.subject.lcsh |
Radiation-sensitizing agents. |
dc.title |
The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway - |
dc.type |
Dissertation |
dc.contributor.department |
American University of Beirut. Faculty of Arts and Sciences. Department of Biology. degree granting institution. |